Randy Milby Continues to Serve as CorMedix's CEO as Hunt for Replacement Continues
Cydan Development Announces Formation of Imara Inc. with $31M Series A Funding to Develop Therapeutic for Sickle Cell Disease
CorMedix Inc (NYSEMKT:CRMD), a pharmaceutical company, disclosed in a regulatory filing late Wednesday that it is still in the process of conducting a formal search for a new chief executive officer. The company added that Randy Milby continues to serve as CEO on the interim and will remain on the board of directors. In July 2015, CorMedix said that its board of directors determined to transition the role of CEO from Milby to an individual with clinical trial management and other management experience that will lead clinical, commercial, and financial oversight and long term vision for the company. Shares closed at $3.96, with a 52-week range of $1.15 – $9.80.
CorMedix Inc (NYSEMKT:CRMD), a pharmaceutical company, disclosed in a regulatory filing late Wednesday that it is still in the process of conducting a formal search for a new chief executive officer. The company added that Randy Milby continues to serve as CEO on the interim and will remain on the board of directors. In July 2015, CorMedix said that its board of directors determined to transition the role of CEO from Milby to an individual with clinical trial management and other management experience that will lead clinical, commercial, and financial oversight and long term vision for the company. Shares closed at $3.96, with a 52-week range of $1.15 – $9.80.